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Anticancer therapies, such as targeting of STAT3 or
the use of anthracyclins (doxorubicin), can induce
cardiomyopathy. In mice prone to developing heart
failure as a result of reduced cardiac STAT3 expres-
sion (cardiomyocyte-restricted deficiency of STAT3)
or treatment with doxorubicin, we observed impaired
endothelial differentiation capacity of Sca-1+ cardiac
progenitor cells (CPCs) in conjunction with attenu-
ated CCL2/CCR2 activation. Mice in both models
also displayed reduced erythropoietin (EPO) levels
in the cardiac microenvironment. EPO binds to
CPCs and seems to be responsible for maintaining
an active CCL2/CCR2 system. Supplementation
with the EPO derivative CERA in a hematocrit-inac-
tive low dose was sufficient to upregulate CCL2,
restore endothelial differentiation of CPCs, and
preserve the cardiac microvasculature and cardiac
function in both mouse models. Thus, low-dose
EPO treatment could potentially be exploited as
a therapeutic strategy to reduce the risk of heart
failure in certain treatment regimens.
INTRODUCTION
Recent studies indicate that the heart exhibits intrinsic regener-
ative capacity during disease and aging, which may attenuate
the progression of heart failure (Hsieh et al., 2007). Activation
and differentiation of resident cardiac progenitor cells have
been implicated in healing processes in response to acute or
chronic myocardial damage (Oh et al., 2003; Torella et al.,
2004). However, only a few intracellular pathways have well-
characterized roles in cardiac progenitor cell proliferation and
differentiation (see Table S1 available online; Madonna et al.,2009; Mohri et al., 2009; Zelaraya´n et al., 2008; Iwakura et al.,
2011). Likewise, little is known about regulatory factors in the
cardiac microenvironment.
The anthracyclin doxorubicin (DOX) has been used effectively
to treat a broad range of cancers. The clinical usage and efficacy
of DOX is, however, restricted by the side effects observed, most
notably heart failure (Ferreira et al., 2008). Similarly, blocking
STAT3 signaling via antisense RNA interference (RNAi),
peptides, or small molecular inhibitors can lead to successful
suppression of tumor cell growth and apoptosis, making
STAT3 an attractive molecular target for the development of
novel cancer therapeutics (Deng et al., 2007). However, it has
also been shown previously that downregulation of STAT3
predisposes the heart to failure (Hilfiker-Kleiner et al., 2004,
2007; Jacoby et al., 2003). Here we analyzedwhether the endog-
enous cardiac regeneration potential of resident Sca-1-positive
cardiac progenitor cells (CPCs) is impaired in failure-prone
hearts of mice with a cardiomyocyte-specific knockout of
STAT3 (aMHC-Cretg/+; STAT3flox/flox, CKO) or in mice exposed
to treatment with DOX.
We observed that in both heart failure models, CPCs display
severely impaired endothelial differentiation capacity that is
related to a reduced activation state of the CCL2/CCR2 system
in the CPCs. We also found that CKO- and DOX-treated mice
display alterations in the cardiac microenvironment that include
a depletion of cardiac erythropoietin (EPO) and discovered
a positive interaction between paracrine EPO and the autocrine
CCL2/CCR2 system in CPCs. Overall, our results suggest that
treatment with synthetic EPO derivatives could preserve the
endothelial differentiation potential of CPCs during certain anti-
cancer treatment programs.
RESULTS
Sca-1+ Cardiac Progenitor Cells Express CCR2
and EPOR but Are Devoid of FLK-1
Freshly isolated Sca-1+ cardiac progenitor cells (CPCs) from
hearts of 3-month-old wild-type mice expressed Nanog andCell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc. 131
Figure 1. Isolation and Characterization of WT-CPCs
(A) FACS analyses of myocardial cells before and after MACS selection for Sca-1 (left and middle; Sca-1+ cardiac cells, green; IgG control, blue). Cytospin of
Sca-1+ CPCs followed by Sca-1 immunohistochemistry (IHC) (right: Sca-1, green; nuclear stain with DAPI, blue). Scale bar represents 50 mm.
(B) RT-PCR for Foxa2, Brachyury, Oct4, Nanog, and Sox2 in freshly isolated CPCs and Sca-1 negative flow through (Flow) in comparison with mouse embryonic
stem cells (ESCs). GAPDH served as control for equal cDNA content.
(C) Confocal microscopy displayed CPCs positive for Sca-1 (green, left), CCR2 (red, second from left), EPOR (purple, middle), DAPI (blue), and merged (second
from right). Isotype control (IgGs for CCR2 and EPOR, right). Scale bars represent 50 mm.
(D) RT-PCR displayed abundance of CCL2 mRNA in liver cells and in freshly isolated WT-CPCs. Loading control used was GAPDH.
(E) Cytospin followed by CCL2 IHC in freshly isolated WT-CPCs (left), liver cells (middle), and isotype control for CCL2 (right). Scale bars represent 50 mm.
(F) EPO mRNA was below detection level by RT-PCR (40 cycles) in freshly isolated WT-CPCs; mouse kidney served as positive control; loading control was
GAPDH.
(G) Cytospin followed by IHC displayed EPO-positive cells (EPO, red; nuclear stain DAPI, blue) among WT-CPCs (left), human embryonic kidney cells (HEK293,
middle) served as positive control, isotype control for EPO (IgG, right). Scale bars represent 50 mm.
(H) IHC showed small cells double positive for EPO (red, DAPI, blue) and Sca-1 (green) in adult WT LVs, right panel displayed larger magnification of area pointed
out by the arrow in the left panel. Scale bar represents 50 mm.
All data were confirmed in at least three independent CPC isolations derived from pooled hearts of 8 to 20 adult male mice. See also Figure S1.
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(Figures 1A and 1B). The expression of surface markers typically
present on hematopoietic or endothelial progenitor cells, CD45,
CD34, CD133, and CD117 (c-kit), or endothelial markers like
FLK-1, VE-Cadherin (CD144), and VCAM-1 (CD106) were not de-
tected, while about 25%of CPCs expressed CD105, 30%CD31,
45% CD13, 60% CD73, 28% CD90, 13% CD29, 17% CD44,
28% the chemokine (C-C motif) receptor-2 (CCR2), and 29%
the erythropoietin receptor (EPOR) (Figure S1). The majority of
CPCs expressing CCR2 were also positive for EPOR (Figure 1C).
Freshly isolated CPCs expressed mRNA and protein of the132 Cell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc.CCR2 ligand CCL2 (Figures 1D and 1E); EPO mRNA was not
detectable despite positive staining for EPO protein (Figures 1F
and 1G). Immunohistology of heart sections revealed EPO/
Sca-1 double-positive small cells located between cardiomyo-
cytes (Figure 1H), suggesting that CPCs bind to EPO protein
present in the cardiac microenvironment.
CPCs Differentiate into Endothelial Cells, Adipocytes,
Fibroblasts, and Pericytes
For in vitro differentiation, CPCs were cultivated for 4 weeks on
fibronectin-coated plates where they formed a closed cell layer
Figure 2. Differentiation Potential of CPCs
(A and B) CPCs differentiated into (A) adipocytes (oil red) and (B) fibroblasts/pericytes (Sca-1, green; vimentin, sm-a-actin, andNG2, red) during in vitro cultivation.
Scale bars represent 50 mm.
(C) Endothelial nets differentiated fromWT-CPCs stained positive for eNOS (red, left), IB4 (green, second from left), VE-Cadherin (red, second from right), FLK-1
(red, right), and DAPI (blue). Scale bars represent 100 mm.
(D) Endothelial nets differentiated from WT-CPCs (IB4, green, middle) are negative for VEGFR3 (red, left), DAPI (blue). Positive control for VEGFR3 staining: liver
(right). Scale bars represent 100 mm.
(E and F) Bar graph (F) summarizing VE-Cadherin mRNA levels (qRT-PCR) and agarose gels showing VE-Cadherin mRNA amplified by RT-PCR (E) in freshly
isolated CPCs, in CPCs after 4 weeks (4W) of in vitro cultivation (LV served as positive control for VE-Cadherin PCR, GAPDH was used to control for equal cDNA
content).
(G) LacZ staining (blue) of CPCs isolated from VE-Cadherin-Cretg/+; ROSA26Rmice stained immediately after isolation (left) and after 4 weeks of in vitro cultivation
(second from left). The parallel flow through of Sca-1-negative cells (second from right) and LV sections (right) from VE-Cadherin-Cretg/+; ROSA26R mice served
as positive control for VE-Cadherin-Cre induction. Scale bars represent 50 mm.
(H) Endothelial nets on matrigel derived from a CPC clone (C25, Table S2) stained for VE-Cadherin (green, left), DAPI (blue, second from left), and VEGFR3 (red,
middle), merged (green/blue, second from right). IgG served as control for specificity of VE-Cadherin staining (right).
(I) RT-PCR revealed expression of CCR2 and EPOR mRNA in expanded single clones C25 and C26 (Table S2), Loading control: GAPDH.
(J) The bar graph summarizes branching points of endothelial nets from sorted Sca-1+ CPCs and Sca-1+/EPOR+/CCR2+ CPCs (*p < 0.05, Sca-1+ CPCs were set
to 100%).
(K) Endothelial net formation (IB4, green; DAPI, blue) of CPCs alone (left) or with the CCR2 blocker RS-102895 (100 nM, middle) or of CCR2-KO-CPCs (right). The
bar graph summarizes number of branching points (WT-CPCs = 100% in each parallel cell isolation, *p < 0.05, **p < 0.01 versus untreated WT-CPCs, scale bars
represent 200 mm).
All data summarize at least three independent CPC isolations derived from pooled hearts of 8 to 20 adult male mice. Error bars indicate SD. See also Figure S2.
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2B), and endothelial cells (Figure 2C). Endothelial cells stained
positive for VE-Cadherin, FLK-1, eNOS, and isolectin B4 (IB4)
but were negative for VEGFR3 (Figures 2C and 2D), indicating
that they displayed a vascular endothelial phenotype (Tammela
et al., 2008). Endothelial differentiation of CPCs during in vitro
cultivation was evident by upregulation of VE-Cadherin and
FLK-1 mRNA (Figures 2E and 2F; Figure S2). To monitor endo-
thelial differentiation, we used VE-Cadherin-Cretg/+; ROSA26R
mice in which endothelial cells are marked by lacZ expression(Benedito et al., 2009). Freshly isolated VE-Cadherin-Cretg/+;
ROSA26R CPCs were initially negative for LacZ staining but
give rise to LacZ-positive endothelial cell nets during in vitro
cultivation (Figure 2G). Endothelial differentiation of CPCs was
also confirmed in CPC clones expanded from single cells.
Five successfully expanded CPC clones maintained an undiffer-
entiated phenotype during expansion as indicated by expres-
sion of Sca-1 and Nanog but not VE-Cadherin (Table S2). Culti-
vation of clones on matrigel was used to stimulate endothelial
differentiation. Two of the five clones underwent vasculogenicCell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc. 133
Table 1. Cardiac Function in WT and CKO Mice with CERA or Saline
WT Baseline WT Saline WT CERA CKO Baseline CKO Saline CKO CERA
%FS 33 ± 7 31 ± 8 32 ± 7 29 ± 10 22 ± 9a 34 ± 5b
LVEDD 4.7 ± 1.0 4.1 ± 0.4 4.2 ± 0.3 4.3 ± 0.5 4.3 ± 0.6 4.1 ± 0.4
LVESD 3.4 ± 0.8 2.8 ± 0.5 3.0 ± 0.5 3.1 ± 0.8 3.3 ± 0.7 2.7 ± 0.4
HR 444 ± 22 448 ± 61 472 ± 35 435 ± 25 477 ± 56 481 ± 54
LV end-diastolic (LVEDD, mm) and end-systolic diameter (LVESD, mm), fractional shortening (%FS), and heart rate (HR, beats/min) determined by
echocardiography.
n = 4 to 10 mice per measurement.
a p < 0.05 versus WT baseline.
b p < 0.05 CKO CERA versus CKO saline.
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staining for VE-Cadherin and negative staining for VEGFR3 (Fig-
ure 2H). Both clones expressed EPOR and CCR2 (Figure 2I),
suggesting that subpopulations that are double positive for
EPOR and CCR2 harbor endothelial differentiation potential.
Enrichment for EPOR/CCR2 double-positive CPCs by FACS
sorting led to higher endothelial differentiation on fibronectin-
coated plates (Figure 2J; VE-Cadherin qRT-PCR, +303% ±
117%, p < 0.05 versus Sca-1-sorted CPCs) compared to Sca-
1-sorted CPCs. Depletion of CD31 did not affect the endothelial
differentiation of CPCs (Figure S2), but blocking CCR2 with RS-
102895 did have an inhibitory effect (Figure 2K; VE-Cadherin
qRT-PCR: 47% ± 8%, p < 0.05 versus WT-CPCs). Consis-
tently, CPCs isolated from CCR2/ knockout mice (CCR2-
KO-CPCs) also displayed impaired endothelial differentiation
(Figure 2K).
Impaired Endothelial Differentiation of CPCs in Mice
with a Cardiomyocyte-Specific Deletion for STAT3
Is Associated with Reduced CCL2/CCR2 Activation
Male mice with a cardiomyocyte-specific STAT3 deletion (CKO)
are prone to develop heart failure with aging (Hilfiker-Kleiner
et al., 2004). CPCs isolated from young CKOmales (CKO-CPCs)
without obvious signs of heart failure (Table 1) displayed
impaired endothelial differentiation compared to CPCs
(WT-CPCs) isolated from corresponding wild-type littermates
(WT: STAT3flox/flox) (Figures 3A and 3B). The impaired endothelial
differentiation of CKO-CPCs was not associated with STAT3
deletion in the CPCs when freshly isolated or after 4 weeks of
in vitro cultivation (Figures 3C and 3D), consistent with the fact
that no aMHC-Cretg/+ transgene activity could be observed in
CPCs isolated from aMHC-Cretg/+; ROSA26R mice (less than
0.001% CPCs stained positive for LacZ; Figure S3). FACS anal-
yses showed that the expression of CCR2 was markedly lower
on CKO-CPCs compared to WT-CPCs while the expression of
EPORwas unchanged (Figure 3E). FACS and qRT-PCR analyses
showed no differences in the expression of CD31, CD105, CD73,
CD13, and CD144 (data not shown) between CKO-CPCs and
WT-CPCs, suggesting that there is no major difference in CPC
subpopulations between the two genotypes.
qRT-PCR revealed no difference in the expression of CCL2
between freshly isolated CKO-CPCs and WT-CPCs (data not
shown). It is known, however, that endogenous CCR2 blockers
can be generated by MMP-12-mediated proteolytic cleavage
of CCL2 into a CCL2 subfragment that then acts as a CCR2
antagonist (Dean et al., 2008). MMP-12 mRNA levels were upre-134 Cell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc.gulated in CKO hearts (qRT-PCR: CKO: +1479% ± 328%, p <
0.01 versus WT) and in CKO-CPCs (qRT-PCR: CKO-CPCs 4W
in vitro cultivation +453% ± 98%, p < 0.01 versus WT-CPCs;
freshly isolated CKO-CPCs +225% ± 203%, p < 0.05 versus
WT-CPCs). Combined addition of the MMP-12 blocker PF-
356231 and recombinant CCL2 (rCCL2) to CKO-CPCs increased
the endothelial differentiation of CKO-CPCs whereas addition of
rCCL2 alone had no significant effect (Figure 3F). Conversely,
addition of recombinant MMP-12 to WT-CPCs impaired their
endothelial differentiation (Figure 3G). Whole tissue extracts
from CKO hearts displayed enhanced cleavage of rCCL2 into
the antagonistic CCL2 subfragment compared to WT tissue
extracts, which could be attenuated by the MMP-12 inhibitor
PF-356231 (Figure 3H).
Erythropoietin Expression Is Reduced in CKO Hearts
Because we observed that CPCs bind EPO protein within the
cardiac microenvironment, we analyzed EPO expression in
CKO hearts. CKO mice displayed a marked reduction in cardiac
EPO protein levels compared to corresponding WT mice
(Figures 4A and 4B; Figure S5), which was associated with
reduced EPOmRNA levels (9-fold lower determined by microar-
ray analysis from five pooled CKO versus five pooled WT LVs,
data not shown). Like cardiomyocytes in the adult mouse heart,
isolated neonatal rat cardiomyocytes (NRCM) expressed and
secreted EPO into the cell culture supernatant (0.013 to
0.402 ng/ml supernatant per 106 seeded cardiomyocytes)
(Figures 4C–4E). EPO in NRCM supernatant was able to induce
erythropoiesis in a methylcellulose-CFU-assay with freshly
isolated murine bone marrow cells (BMC). The erythropoiesis
capacity of NRCM supernatant was lost after heat inactivation
(Figure 4E) or if supernatant derived from NRCM where EPO
had been downregulated by siRNA (Figure 4F). Knockdown of
STAT3 using a shRNA-lentivirus in NRCM resulted in a 2-fold
reduction of EPO protein levels compared to NRCM infected
with a control lentivirus (Figure 4D), suggesting that EPO expres-
sion in NRCM depends in part on STAT3.
Treatment of CKO Mice with the EPO Derivative
CERA Upregulates CCL2 and Restores Endothelial
Differentiation of CKO-CPCs but Has No Effect
in CPCs from CCR2 Knockout Mice
To investigate whether exogenous supplementation of the CKO
myocardiumwith EPO could restore endothelial differentiation of
CKO-CPCs in vivo, a 3 week treatment with the EPO derivative
CERA (continuous erythropoiesis receptor activator, that is
Figure 3. CKO-CPCs Displayed Impaired Endothelial Net Formation as a Potential Consequence of Modulated CCR2 Activity
(A and B) Impaired endothelial net formation (IB4, green; DAPI, blue) of CKO-CPCs (right) compared to WT-CPCs (left), scale bars in upper panels represent
200 mmand in lower panels represent 100 mm, the bar graph summarizes number of branching points (WT-CPCs = 100% in each set, **p < 0.01) (A) and qRT-PCR
for VE-Cadherin in WT-CPCs and CKO-CPCs after 4 weeks of cultivation (WT-CPCs = 100%, *p < 0.05) (B).
(C) Agarose gel depicting PCR-based detection of wild-type STAT3, floxed STAT3, and flox-deleted STAT3 alleles in genomic DNA from a heterozygous Cretg/+;
STAT3flox/+ (1) and a wild-type mouse heart (2), from freshly isolated WT-CPCs (STAT3flox/flox) (3) and CKO-CPCs (Cretg/+; STAT3flox/flox) (4), and from WT-CPCs
(STAT3flox/flox) (5) or CKO-CPCs (Cretg/+; STAT3flox/flox) after 4 weeks in culture (6).
(D) Representative western blot displayed similar levels of STAT3 protein in WT-CPCs and CKO-CPCs after 4 weeks of culture; loading control was actin.
(E) Quantification of EPOR (top) and CCR2 (bottom) in freshly isolated CKO-CPCs and WT-CPCs by FACS.
(F) Bar graph summarizes number of branching points in CKO-CPC cultures alone (set at 100%), with addition of rCCL2 or with addition of rCCL2 and PF-356231
(*p < 0.05 versus untreated CKO-CPCs).
(G) Endothelial net formation (IB4, green; DAPI, blue) of WT-CPCs alone (left) and with addition of rMMP-12 (200 ng/ml; right). The bar graph summarizes number
of branching points (WT-CPCs = 100% in each parallel cell isolation, *p < 0.05, versus untreated WT-CPCs). Scale bars represent 200 mm.
(H) Western blot depicted CCL2 forms generated from recombinant CCL2 (rCCL2: 3.6 mg/ml LV extract), antagonistic rCCL2 (ant. rCCL2) by WT and CKO heart
extracts ex vivo with or without addition of the MMP-12 inhibitor PF-356231 (30 nM).
All results derive from three to seven independent cell isolations pooled from 8 to 20 adult male mice. Error bars indicate SD. See also Figure S3.
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dose that did not increase the hematocrit (3 mg/kg/week; Fig-
ure S4) was used. Low-dose CERA had no influence on the
recruitment of BMC to the myocardium as indicated by similar
numbers of X-gal-positive cells in wild-type mice transplanted
with bone marrow from ROSA26 mice expressing the bacterial
lacZ gene (Figure S4). In freshly isolated CKO-CPCs from
CERA-treated mice, CCL2 mRNA levels were markedly higher
and MMP-12 mRNA levels were lower compared to CKO-CPCs
from placebo-treated CKO mice (Figure 4G). Endothelial differ-
entiation of CKO-CPCs was substantially higher in CERA
compared to placebo-treated CKO mice after in vitro cultivation(Figure 4H; VE-Cadherin qRT-PCR: CKO-CPCs/CERA, +157%±
5%, p < 0.05 versus CKO-CPC/placebo). Expression of Delta-
like 4 (Dll4) a marker for sprouting activity of endothelial cells
(Nakagami et al., 2006) was readily detectable in sprouting
ends of endothelial nets formed by WT-CPCs or CKO-CPCs
from CERA-treated CKO mice but was only marginal in CKO-
CPCs from placebo-treated CKO mice (Figure 4I). CERA
treatment had no additional effect on endothelial differentiation
of WT-CPCs (Figure 4H). In contrast to CKO-CPCs, CERA
treatment of CCR2-KO mice did not improve endothelial differ-
entiation of CCR2-KO-CPCs (qRT-PCR for VE-Cadherin: +5% ±
8% with CERA, n.s. versus CCR2-KO-CPCs/saline).Cell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc. 135
Figure 4. Endogenous EPO Is Reduced in CKO Mice; Supplementation with the EPO-Derivative CERA Exerts Positive Effects on CPCs and
the Cardiac Phenotype of CKO Mice
(A) Representative IHC showed EPO (red) located in cardiomyocytes (positive for a-sarcomeric actinin; a-actinin, green) in WT (top) and CKO (bottom) LV
sections, overlay of EPO/a-actinin: red/green, DAPI (blue), isotype control for EPO (IgG/DAPI). Scale bars represent 25 mm.
(B)Western blot depicted EPO protein levels in LVs fromWT,CKO, and EPO-TAghmice. Loading control was actin. The bar graph summarizes EPOprotein levels,
*p < 0.05, **p < 0.01 versus WT.
(C) IHC visualizing EPO protein (green, double-stained with anti-a-actinin red, nuclear stain with DAPI, blue; top) in cultured neonatal rat cardiomyocytes (NRCM),
isotype control for EPO (IgG, DAPI; bottom).
(D) Western blot depicted EPO protein levels in NRCM transduced with control lentivirus (C) or shSTAT3-RNA lentivirus (shSTAT3). Loading control was actin.
(E) Outgrowth of erythroid colony- and burst-forming units (CFU-/BFU-E) from freshly isolated mouse BMC in methylcellulose assays with no addition of rEPO
(negative control; bottom left), supplemented with rEPO (positive control; top right) or cell culture supernatant from NRCM, native or heat inactivated (lower left
and right).
(F) qRT-PCR for EPO expression in NRCM treated with scrambled or EPO siRNA. Outgrowth of erythroid CFU-/BFU-E from freshly isolated mouse BMC in
methylcellulose assays with cell culture supernatant from NRCM treated with scrambled siRNA (left) or EPO siRNA (right).
(G) Bar graphs depicting CCL2 and MMP-12 mRNA levels (qRT-PCR) in freshly isolated CKO-CPCs from saline or CERA-treated CKO mice (saline-treated mice
were set at 100%, *p < 0.05).
(H) Endothelial net formation (IB4, green) of WT-CPCs or CKO-CPCs isolated from saline or CERA-treated WT and CKO mice, number of branching points were
summarized in the bar graph (WT-CPCs = 100% in each isolation, **p < 0.01 versus WT-CPCs saline, ##p < 0.01 CKO-CPCs with CERA versus CKO-CPCs
control). Scale bars represent 200 mm.
(I) Sprouting ends of endothelial nets stained with antibodies against Delta-like 4 (Dll4, red), IB4 (green), and DAPI (blue), and isotype control for Dll4. Scale bars
represent 50 mm.
(J) The capillary to cardiomyocytes ratio summarized in the bar graph from LV sections of CKOmice treated with saline or CERA (**p < 0.01 versus saline-treated
CKO).
All results derive from four to sixmice per group and from three independent cell isolations pooled from six to tenmice. Error bars indicate SD. See also Figures S4
and S5.
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Figure 5. Recombinant EPO Improved Endothelial Net Formation and IncreasedCCL2Expression in CKO-CPCCultures but HadNoEffect on
CCR2-KO-CPCs
(A) Endothelial nets (IB4, green) in WT-CPC (left) or CKO-CPC (right) cultures with or without addition of rEPO (1.2 U/ml). Scale bars represent 200 mm. The bar
graph summarizes number of branching points of endothelial nets (nontreated WT-CPC cultures were set at 100%, **p < 0.01 versus nontreated WT-CPCs;
##p < 0.01 rEPO treated versus nontreated CKO-CPCs).
(B) Bar graph summarizing VE-Cadherin mRNA levels (qRT-PCR) in WT-CPCs and CKO-CPCs cultured with or without rEPO (*p < 0.05 versus nontreated
WT-CPCs).
(C) Sprouting ability of CKO-CPCs on matrigel with (bottom) or without addition of rEPO (top), number of branching points were summarized in the bar graph;
**p < 0.01 versus nontreated CKO-CPCs. Scale bars represent 50 mm.
(D) The bar graphs summarize CCL2 and MMP-12 mRNA levels (qRT-PCR) in CKO-CPC cultures with or without addition of rEPO (nontreated CKO-CPC
cultures = 100%, *p < 0.05).
(E) Endothelial nets (IB4, green) in parallel cultures of WT-CPCs (set 100%; top left) with RS-102895 (top right) or with RS-102895 and rEPO (bottom left) (number
of branching points were summarized in the bar graph, *p < 0.05, versus WT-CPC cultures). Scale bars represent 100 mm.
(F) Bar graph summarizing number of branching points in parallel cultures of WT-CPCs and CCR2-KO-CPCs (**p < 0.01, versus WT-CPC cultures).
Results in all experiments derive from three to seven cell isolations each from pools of eight to ten mouse hearts. Error bars indicate SD. See also Figure S5.
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Capillary Density without Altering the Inflammatory
Status in CKO Mice
In line with previous data (Hilfiker-Kleiner et al., 2004), placebo-
treated CKO mice displayed a diminishment of capillaries,
a decrease in LV function (Table 1), and an increase in atrial natri-
uretic peptide (ANP) mRNA expression (ANP qRT-PCR: CKO
placebo: +691% ± 453%, p < 0.05 versus placebo-treated WT)
compared to placebo-treated WT mice. CERA treatment pre-
vented the reduction in capillary density (Figure 4J), the decrease
in LV function (Table 1), and the increase in ANP mRNA expres-
sion (CKO CERA: +136% ± 204%, n.s. versus placebo-treated
WT). CERA treatment did not alter the number of CD45-positive
inflammatory cells, mainly macrophages and leukocytes, in CKO
hearts (Figure S4). In contrast to CKO hearts, CERA had no effect
on the myocardial capillary density (capillaries/cardiomyocytes
in WT placebo: 1.61 ± 0.1 versus WT CERA: 1.58 ± 0.06, n.s.),the cardiac function (Table 1), or the ANP expression
(WT CERA: 7% ± 82%, n.s. versus WT placebo) in WT mice.
Addition of Recombinant EPO Improves Endothelial
Differentiation of CKO-CPCs In Vitro but Has No Effect
on WT-CPCs with Blocked CCR2 or on CCR2-KO-CPCs
To analyze whether EPO directly improved the endothelial differ-
entiation of CKO-CPCs, recombinant mouse EPO (rEPO) was
added to CKO-CPCs during in vitro cultivation. Figures 5A and
5B show that rEPO significantly improved endothelial differenti-
ation of CKO-CPCs but did not affect that of WT-CPCs. In
contrast to rEPO, rVEGF could not improve endothelial differen-
tiation of CKO-CPCs (Figure S5). Addition of rEPO increased
also the sprouting ability of CKO-CPCs on matrigel (Figure 5C)
and markedly increased CCL2 expression in CKO-CPCs, but
had no effect on MMP-12 expression (Figure 5D). A luciferase
reporter plasmid harboring the putative CCL2 promoterCell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc. 137
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CCR2 and Cardiac Progenitor Cell Differentiation(nucleotides –3043 to 21, relative to the transcription start of
CCL2) showed that rEPO augmented CCL2 promoter activity
(Figure S5).
In contrast to CKO-CPCs, rEPO was not able to improve
impaired endothelial differentiation in WT-CPCs treated with
the CCR2 blocker RS-102895 (Figure 5E, confirmed by
qRT-PCR for VE-Cadherin: rEPO/RS-102895: 68% ± 10%
versus RS-102895: 47% ± 15%, n.s.). Similarly, rEPO could
not rescue the impaired endothelial differentiation seen in
CCR2-KO-CPCs (Figure 5F).
Doxorubicin Treatment Decreases CCL2 Expression
and Impairs Endothelial Differentiation of CPCs and
Lowers Cardiac EPO Protein Levels
We analyzed the CPC phenotype in a second model of progres-
sive heart failure based on doxorubicin-induced cardiomyopathy
(DOX: 6 mg/kg/week for 3 weeks) in wild-type mice (8-week-old
male Balb/C mice). CPCs isolated from DOX-treated mice
(DOX-CPCs) displayed impaired endothelial differentiation
(Figures 6A and 6B) and reduced CCL2 expression (Figure 6C)
compared to CPCs from placebo (saline)-treated control mice,
whereas MMP-12 expression was not affected (Figure 6C).
DOX treatment reduced cardiac EPO protein levels (Figure 6D).
Addition of DOX to NRCM markedly lowered their STAT3 and
EPO expression (Figure 6E).
CERA Preserves CCL2 Expression and Endothelial
Differentiation in CPCs, Maintains Cardiac Capillary
Density and Cardiac Function, and Improves Survival
of Doxorubicin-Treated Mice
Low-dose CERA (3 mg/kg/week) starting 1 day before DOX treat-
ment prevented impairment of endothelial differentiation (Fig-
ures 6A and 6B, qRT-PCR for VE-Cadherin: DOX-CPCs/
CERA: +75% ± 45%, p < 0.05 versus DOX-CPCs/placebo) and
preserved CCL2 expression in DOX-CPCs (Figure 6C). As
observed by others (Kunisada et al., 2000), DOX reduced cardiac
capillary density, induced heart failure, and caused a high
mortality rate in mice; all of these features were markedly atten-
uated by cotreatment with CERA (Figures 6F–6H).
EPO Protein Expression Is Reduced in End-Stage Failing
Human Hearts
We previously described a group of patients with end-stage
heart failure resulting from dilatative cardiomyopathy (DCM) or
ischemic cardiomyopathy (ICM) that displayed a substantial
reduction of STAT3 protein levels in LV tissue compared to non-
failing hearts (NF) (Podewski et al., 2003). We found that in LV
tissue samples of the same hearts, EPO protein levels were
reduced (Figure S6), highlighting a parallel between our findings
in mouse and human hearts with cardiomyopathy.
DISCUSSION
We present evidence that subpopulations of CPCs can differen-
tiate in endothelial cells, adipocytes, and fibroblasts/pericytes.
As observed by others (Oh et al., 2003), CPCs express the
typical surface markers CD45, CD34, CD117 (c-kit), CD133,
and FLK-1 that are present on bone-marrow-derived progenitor
cells at a very low level if at all, suggesting that they constitute138 Cell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc.a distinct population of residential progenitor cells within the
heart. Clonal expansion of CPCs revealed stable expression
patterns of Sca-1 and Nanog but no expression of VE-Cadherin.
Under endothelial differentiation conditions on matrigel, CPC
clones expressing CCR2 and EPOR were able to differentiate
in VE-Cadherin-positive, VEGFR3-negative (Tammela et al.,
2008) vasculogenic endothelial cells, a property confirmed in
CPCs carrying the endothelial VE-Cadherin reporter system.
Some CPCs exhibit a mesenchymal progenitor cell-like pheno-
type as indicated by the surface markers CD13, CD73, CD29,
CD44, and CD90 (Pittenger and Martin, 2004) and differentiation
into cell types of the mesenchymal lineage, i.e., adipocytes,
fibroblasts, and pericytes, indicating that CPCs consist of
a heterogeneous population of progenitor cells with distinct
differentiation potentials.
The CCL2/CCR2 system is important for neoangiogenesis
during tissue regeneration, as shown by the fact that CCR2-
KO mice display delayed neoangiogenesis in injured skeletal
muscle (Contreras-Shannon et al., 2007). We confirmed previ-
ously described (Salcedo et al., 2000) direct proangiogenic
signaling via the CCR2 on endothelial cells and expand the
angiogenic role of CCR2 from mature endothelial cells to endo-
thelial differentiation of CPCs, as CPCs lacking CCR2 function
through deletion or pharmacological block display substantially
lower endothelial differentiation capacities. It is important to
note that with these assays we cannot distinguish whether
the CCL2/CCR2 system primarily promotes endothelial differen-
tiation fromCPCs and/or promotes branching of endothelial cells
differentiated from CPCs.
We detected an attenuated CCL2/CCR2 system associated
with impaired endothelial differentiation in CPCs isolated from
failure-prone hearts of CKO mice (Hilfiker-Kleiner et al., 2004)
and in failing hearts from WT mice exposed to DOX. Impair-
ment of the CCL2/CCR2 system in CKO-CPCs results from
alterations in the cardiac microenvironment caused by the
STAT3 deficiency in cardiomyocytes and includes reduced
expression of CCR2 and impaired autocrine CCL2 signaling
due to enhanced generation of antagonistic CCL2 fragments.
We do not have evidence for a shift in Sca-1+ subpopulations
because other surface markers were not different relative to
WT-CPCs. Increased MMP-12 expression in CKO-CPCs and
CKO hearts was responsible for the proteolytic cleavage of
CCL2 in its antagonistic fragment. We speculate that the re-
sulting CCR2 antagonism may result in a negative feedback
mechanism that could explain the downregulation of CCR2
on CKO-CPCs. We have no explanation why the expression
of MMP-12 is upregulated in cardiac tissue of CKO mice and
in isolated CKO-CPCs. However, we conclude that the upre-
gulation of MMP-12 and the subsequent generation of antago-
nistic CCL2 plays a crucial role for impaired endothelial
differentiation of CKO-CPCs, because (1) enhanced MMP-
12-mediated CCL2 cleavage was observed in CKO hearts,
a finding that is consistent with previous reports showing
that MMP-12 cleaves CCL2, -7, -8, and -13 in CCR antago-
nists (Dean et al., 2008); (2) inhibition of MMP-12 activity and
addition of rCCL2 improved endothelial differentiation of
CKO-CPCs, whereas addition of rCCL2 alone had no effect;
(3) addition of rMMP-12 to WT-CPCs impaired their endothelial
differentiation; and (4) improved endothelial differentiation of
Figure 6. Negative Effect of Doxorubicin on Cardiac EPOExpression, CPC Phenotype, Capillary Density, Cardiac Function, and Survival Was
Attenuated by CERA
(A) Endothelial net formation (IB4, green) of CPCs isolated from saline control (Con: set at 100% in parallel cultures; left) and of DOX-CPCs in vivo treated with or
without CERA (right and middle) followed by 4 weeks in vitro cultivation. The bar graph summarizes number of branching points (Con-CPCs = 100% in each
isolation). Scale bars represent 50 mm.
(B) The bar graph shows VE-Cadherin mRNA (qRT-PCR) levels of Con-CPCs (set at 100% in parallel cultures; *p < 0.05 versus Con-CPCs) and DOX-CPCs after
in vivo treatment with or without CERA followed by 4 weeks in vitro cultivation.
(C) Bar graphs summarizing qRT-PCR for CCL2 and MMP-12 mRNA levels in freshly isolated Con-CPCs (set at 100% in parallel cultures) and DOX-CPCs after
in vivo treatment with or without CERA, **p < 0.01 versus Con-CPCs.
(D) Western blot depicting EPO protein levels in Con and DOX mice, the bar graph summarizes EPO protein levels, *p < 0.05 versus Con mice.
(E) Western blot depicting EPO and STAT3 protein levels in NRCM treated with DOX; loading control, Actin.
(F–H) The bar graph summarizes ratios of capillaries/cardiomyocytes (F), the fractional shortening (%FS) determined by echocardiography (G), and the Kaplan
Meier survival curve in Con mice or DOX mice treated with saline or CERA (H) (*p < 0.05, **p < 0.01 versus WT mice/saline; **p < 0.01 #DOX mice/CERA versus
DOX mice/saline).
All results (A–H) derive from 5–18 mice per group and 3 independent cell isolations (pools of 6–10 mice).
(I) Scheme explaining how cardiac STAT3 deficiency or DOX may impair the endogenous cardiac vasculogenic regeneration potential. Middle: In the normal
heart, STAT3-dependent paracrine factors possibly including EPO are secreted from cardiomyocytes (CM) into the cardiac microenvironment to maintain the
endothelial differentiation capacity of CPCs into endothelial cells (EC) a characteristic that involves the autocrine CCL2/CCR2 system on CPCs. Left: Cardiac
STAT3 deficiency (STAT3-KO) alters the cardiac microenvironment, i.e., diminishes EPO protein levels and impairs the CCL2/CCR2 system on CPCs by reducing
CCR2 and by promoting MMP-12 expression. MMP-12 generates cleaved antagonistic CCL2 (ant. CCL2). As a result, CCR2 signaling is hampered and
endothelial differentiation of CPCs is reduced. DOX affects the cardiac microenvironment in a similar way (in part also via reducing STAT3) as evidenced by
decreased EPO levels. In addition, DOX reduces CCL2 expression of CPCs and thereby reducesCCR2 activity, leading to attenuated endothelial differentiation of
CPCs. This impaired endothelial differentiation of CPCs in STAT3 deficiency and DOX treatment diminishes the cardiac vasculature and contributes to heart
failure. Right: In treatment regimens using DOX or STAT3 reduction, low-dose CERA supplementation increases the activation state of the CCL2/CCR2 system in
the heart and specifically in CPCs thereby protecting vascular cells and potentially also the cardiomyocyte compartment.
Error bars indicate SD. See also Figure S6.
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ciated with upregulated CCL2 and reduced expression of
MMP-12.In DOX-CPCs, CCR2 and MMP-12 expression were normal,
but CCL2 expression was markedly reduced. As EPO directly
increases CCL2 promoter activity, the reduced CCL2 expressionCell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc. 139
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CCR2 and Cardiac Progenitor Cell Differentiationin DOX-CPCsmaybeat least in part a consequenceof lower EPO
levels in the cardiac microenvironment of DOX-treated mice. In
fact, DOX reduced EPO expression in cardiomyocytes in vitro.
Furthermore, CPCs bind EPO in the cardiac microenvironment
since EPOproteinwasdetected on freshly isolatedCPCswithout
evidence that these cells expressed EPO mRNA themselves.
Upregulation of endogenous cardiac EPO signaling has been
described during ischemic insults (Lin et al., 2008; Tada et al.,
2006) and in pressure overload-induced LV dysfunction (Asaumi
et al., 2007).We observed low levels of endogenous cardiac EPO
in adult mouse and human hearts that seem to be derived at least
in part from cardiomyocytes that express and secrete EPO under
normoxic conditions. Cardiomyocyte STAT3 appears important
for this basal cardiac EPO expression as EPO protein levels
were lower in CKOmice, in end-stage failing humanmyocardium
with reduced STAT3 expression (Podewski et al., 2003) and in
isolated cardiomyocytes with shRNA-mediated STAT3 knock-
down. Consistent with our data, a 4-fold downregulation of
EPO expression in hearts from patients with nonischemic heart
failure has been described via microarray analysis (E-GEOD-
1869) (Kittleson et al., 2005). Moreover, it has been reported
that DOX reduces myocardial STAT3 expression (Kunisada
et al., 2000), a feature that we confirmed in isolated cardiomyo-
cytes. In line with a proposed role for STAT3 in cardiac EPO
expression, we observed that hearts and cultured cardiomyo-
cytes exposed to DOX treatment displayed reduced EPO protein
levels. We do not know at this point precisely how the lower
endogenous EPO protein level in hearts from CKO and DOX
mice affects their cardiac phenotype. However, we found that
treatment of CKO-CPCs with rEPO in vitro or treatment of CKO
mice and DOX mice in vivo with the EPO derivative CERA upre-
gulated CCL2 expression and improved endothelial differentia-
tion, apparently mainly via the CCL2/CCR2 system, because
rEPO (in vitro) or CERA (in vivo) could not improve endothelial
differentiation of CCR2-KO-CPCs. rEPO was also not able to
rescue impaired endothelial differentiation in WT-CPCs with
pharmacologically blocked CCR2. Previous studies have shown
that non-hematocrit-inducing EPO derivatives can also directly
protect cardiomyocytes from apoptosis (Ueba et al., 2010).
EPO treatment also induced CCL2 promoter activity in cardio-
myocytes and, because CCL2 can protect cardiomyocytes
from apoptosis (Tarzami et al., 2005) and promote regeneration
of cardiomyocytes by inducing migration of neuronal crest cells
into the injured heart (Tamura et al., 2011), the link between EPO
and CCL2 signaling may be beneficial not only for the cardiac
vasculature but also for other cardiac cells. The cardioprotective
effect seen with CERA treatment in the two mouse models that
we studied could therefore be multifaceted. It is also consistent
with recently published data indicating that low-dose hemato-
crit-inactive or nonerythropoietic synthetic EPO-mimicking
compounds exert protective effects in cardiomyopathies
(Vogiatzi et al., 2010; Bergmann et al., 2011). In contrast,
however, hematocrit-increasing high doses of EPO seem to be
problematic in the treatment of cardiomyopathies, especially
myocardial infarction (Najjar et al., 2011).
Our finding that EPO did not further enhance endothelial differ-
entiation in wild-type CPCs and that CERA had no specific
proangiogenic effect in normal hearts suggests that it is not
inducing supranormal angiogenesis, which might be an impor-140 Cell Stem Cell 9, 131–143, August 5, 2011 ª2011 Elsevier Inc.tant aspect with regard to a potential use of EPO derivatives
for cardioprotection (and possibly also protection of other
organs) during antitumor strategies involving DOX treatment or
STAT3 inhibition. Importantly, there is already evidence that
EPO does not promote tumor growth during DOX treatment
(Chen et al., 2007; Gewirtz et al., 2006). This activity profile
contrasts positively with other cardioprotective proangiogenic
factors, such as VEGF, that clearly promote tumor angiogenesis
and therefore could not be used to protect the heart during anti-
cancer therapies.
In conclusion, our report highlights the importanceof theCCL2/
CCR2system for sustaining theendogenousvasculogenic regen-
eration potential of CPCs and potentially also endothelial cells in
a VEGF-independent manner in the adult heart. In failure-prone
situations induced by cardiotoxic antitumor therapies with DOX
or STAT3 deficiency, the CCL2/CCR2 system is disrupted due
to impaired autocrine mechanisms in CPCs and impaired para-
crine systems possibly involving cardiomyocyte-derived EPO.
However, treatment with rEPO or the EPO-derivative CERA
preserved the endothelial differentiation of CPCs in CKO and
DOXmice by upregulating CCL2 and preserved cardiac vascula-
ture and function in vivo. Therefore, EPO administration at low,
hematocrit-inactive, doses seems an attractive avenue to pursue
for protecting the heart during antineoplastic drug therapy and
might also have broader applications in cardiac regeneration.
EXPERIMENTAL PROCEDURES
Recombinant human fibroblast growth factor (rhFGF-basic, R&D systems),
cell culture medium (DMEM/F12 1:1), HBSS, and PBS were from GIBCO,
Invitrogen. All other chemicals were from SIGMA-ALDERICH.
Patient Data
LV tissues were from patients undergoing heart transplantation due to end-
stage heart failure caused by dilatative (DCM, n = 4) or ischemic (ICM, n = 2)
cardiomyopathy. LV tissue from donor hearts not suited for transplantation
served as control (NF, n = 6).
Animal Experiments
3-month-old male mice with a cardiomyocyte-restricted knockout of STAT3
(CKO: aMHC-Cretg/+; STAT3flox/flox) and wild-type (WT: STAT3flox/flox) mice
were used as described previously (Hilfiker-Kleiner et al., 2004). Crossing
aMHC-Cretg/+ mice to ROSAflox/flox mice generated aMHC-Cretg/+; ROSA26R
mice. The tamoxifen-inducible VE-Cadherin-Cre mice were crossed with
ROSAflox/flox to generate VE-Cadherin-Cretg/+; ROSA26R reporter mice and
induced as described (Benedito et al., 2009). Generation of EPO-TAgh mice
for experimental controls is described (El Hasnaoui-Saadani et al., 2009).
CCR2/ and ROSA26R mice were purchased from the Jackson Laboratory.
C57Bl/6 and Balb/C mice were from Charles River.
Mice were injected weekly (i.p.) with CERA dissolved in saline (3 mg/kgBW
Mircera, Roche) or with saline for 3 subsequent weeks. Balb/c mice (8 weeks
old) were injected weekly (i.p.) with doxorubicin hydrochloride (DOX) dissolved
in saline (6 mg/kgBW DOX/week, SIGMA) or with saline or CERA (3 mg/kgBW
Mircera, Roche) for 3 subsequent weeks. Echocardiography was performed in
sedated mice (isoflurane inhalation 0.5%) using a Vevo 770 (Visual Sonics) as
described (Hilfiker-Kleiner et al., 2007).
All animal studies were in compliance with the Guide for the Care and Use of
Laboratory Animals as published by the U.S. National Institutes of Health and
were approved by our local Institutional Review Boards.
Isolation, Characterization, and Cultivation of Sca-1+ Cardiac
Progenitor Cells
The Sca-1-FITC microbead kit with the Magnetic Cell Sorting (MACS) system
(Miltenyi Biotec) was used for isolation of Sca-1+ cells from mouse hearts
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CCR2 and Cardiac Progenitor Cell Differentiation(Oh et al., 2003; Supplemental Experimental Procedures). The protocol for
clonal expansion of CPCs is given in the Supplemental Information. Purity
and marker profile of freshly isolated CPCs was determined by FACS analysis
(FACS Calibur and LSRII, BD Biosciences) with antibodies against Sca-1,
CD31, CD34, CD45, CD144, CD106, CD13, CD29, CD44, CD73, CD90
(BD PharMingen), CD4, CD105, c-kit (CD117), prominin-1 (CD133) (Miltenyi
Biotech), CD144 (eBioscience), CCR2 (Abcam), EPOR, and FLK-1 (Santa
Cruz Biotechnology). In most experiments, MACS-isolated CPCs were used.
Only where specifically indicated, CPCs were subsequently sorted by FACS
(MoFlow, XPD Upgrade, Beckman-Coulter) for EPOR (Santa Cruz Biotech-
nology) and CCR2 (Abcam) and seeded on fibronectin-coated wells. Mouse
rEPO (1.2 U/ml, R&D Systems), mouse rMMP-12 (200 ng/ml, R&D Systems),
mouse rVEGF (100 ng/ml; SIGMA), the CCR2-inhibitor RS-102895 (100 nM,
SIGMA), rCCL2 (100 ng/ml; Immunotols), or the MMP12-inhibitor PF-356231
(30 nM, Enzo Life Science) were added to CPCs cultures 24 hr after seeding
and replaced every 3rd day. Controls were supplemented with the same
volume of PBS or DMSO.
Isolation and Transduction of Neonatal Rat Cardiomyocytes
Isolation and cultivation of neonatal rat cardiomyocytes (NRCM) were
described previously (Hilfiker-Kleiner et al., 2004). Generation of anti-c-
STAT3-small-hairpin-RNAs (shRNA) corresponding to position 823 to 841 of
the murine c-STAT3 gene (Genbank accession number NM-213659), lentiviral
transgene plasmids pdc-SR, and shRNA was described previously (Haghikia
et al., 2010). Scrambled siRNA or EPO siRNA (Santa Cruz Biotechnology)
were transfected into NRCM by Lipofectamin 2000 (Invitrogen). NRCM were
treated for 24 hr with DOX (0.01 and 0.05 mg/ml).
Colony-Forming Cell Assays for Mouse Cells
Freshly isolated BMCs (tibia and femur) from C57Bl/6 mice (2 3 104 cells per
35 mm dish) were used to analyze the colony-forming activity in semisolid
methylcellulose (Methocult GF M3534, StemCell technologies) according to
the manufacturer’s protocol with slight modifications (Miller and Lai, 2005)
supplemented with rEPO (3 U/ml, positive control) or concentrated NRCM-
supernatants (103), cells were analyzed with an Axiovert 200Mwith Axiovision
4.6 software (Carl Zeiss).
Matrigel Tube Formation Assay
Matrigel tube formation assay was performed as described by Tepper et al.
(2002). In brief, a 48-well plate was precoated with 100 ml Matrigel (GFR base-
ment membrane matrigel matrix, BD Biosciences). CPCs were seeded at
a density of 1.25 3 104 cells per well in DMEM/F12 (1:1) with 2% FBS and
1.2 U/ml rEPO. Control medium was supplemented with the same volume of
PBS. The number of sprouts per cell was determined.
Immunohistochemistry
For immunohistochemistry, CPCs (cytospins and cultures), and NRCM were
fixed with 4% paraformaldehyde (PFA). LV cryosections were fixed with
ice-cold acetone as described (Hilfiker-Kleiner et al., 2004). After air-drying
and rehydration in 13 PBS, the protocols from vectastain were used with
the following antibodies: eNOS (Dianova), CD144 (VE-Cadherin) (Bender
Medsystems), CD45, CD144, Ly-6G+C, VEGFR3 (BD PharMingen), aActinin,
sm-a-actin (SIGMA), vimentin (Dako), NG2 (Millipore), CCR2, Dll4 (Abcam),
Moma-2 (Acris), CCL2, EPO, EPOR, and FLK-1 (Santa Cruz Biotechnology)
or with IB4 (Vector). For nuclear staining DAPI, Hoechst 33258 (SIGMA) or
hematoxyline was used. Images were taken by fluorescence microscopy
with Axiovision 4.6 software (Carl Zeiss, Jena, Germany) or by confocal laser
microscopy (Leica DM IRB with TCS SP2 AOBS scan head). X-gal staining
is depicted in the Supplemental Experimental Procedures.
Quantification of Endothelial Nets
Net formation capacity was determined by quantification of branching points
per net and cell culture plate after IB4 (Vector) and DAPI staining.
Capillary Density
Capillary density was determined as the ratio of capillaries to cardiomyocytes
in transversely sectioned LVs stained IB4 (Vector) and with wheat germ agglu-tinin (WGA, Vector) and Hoechst 33258, as described previously (Hilfiker-
Kleiner et al., 2007).
Isolation of RNA and qRT-PCR
Total RNA isolation from adult murine heart, kidney, liver, CPCs, and NRCM
and qRT-PCR (Brilliant SYBR Green Mastermix-Kit, Stratagene) performed
with the Stratagene MX3005P multiplex QPCR System was described
previously (Hilfiker-Kleiner et al., 2007). Primer sequences are provided in
the Supplemental Experimental Procedures.
Generation of the CCR2 Antagonizing Cleavage Product
WT and CKO hearts were minced and resuspended in 70 ml DMEM per 25 mg
of tissue supplemented with rCCL2 (250 ng) and/or PF-356231 (30 nM) over
6 hr at 37C.
Luciferase Assay
Cloning of the putative CCL2-promoter in the luciferase reporter plasmid
pGL4.12 is described in the Supplemental Information. NRCMwere transiently
transfected with 3 mg DNA/well of mouse CCL2 promoter-pGL4.12 luc
construct or with pGL4.12 luc (Promega) using Lipofectamin 2000 (Invitrogen).
12 hr after transfection, cells were stimulated with EPO (1.2 U/ml), TNFa
(10 ng/ml), and LPS (4 mg/ml). After 24 hr stimulation, cells were harvested
and luciferase activity was determined by using dual-luciferase reporter assay
system (Promega) according to manufacturer’s protocol.
Immunoblotting
Immunoblots were performed according to standard procedures using
SDS-PAGE (Hilfiker-Kleiner et al., 2004). The following antibodies were used:
Actin (SIGMA), STAT3 (Cell Signaling), EPO (BD PharMingen; Santa Cruz
Biotechnology), and CCL2 (Santa Cruz Biotechnology).
EPO ELISA
Concentrations of EPO in cardiomyocyte supernatants were measured using
a commercial EPO enzyme-linked-immunosorbent assay according to the
manufacturer’s protocol (Quantikine, R&D Systems).
Statistical Analyses
Data are presented as mean ± SD. Differences between groups were analyzed
by Student’s t test or ANOVA followed by Bonferroni as appropriate. A two-
tailed p value of < 0.05 was considered to indicate statistical significance.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE30306.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at doi:10.
1016/j.stem.2011.07.001.
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